Project Grant K24HL188697
Award Date 9/1/26
Completion Date 8/31/31
Dollars Obligated $137K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Birmingham, AL 35294, USA
Similar Awards
- The National Institutes of Health Office of the Director awarded the Board of Regents of the University of Nebraska, acting through its University of Nebraska Medical Center division, $565,185 on August 17, 2026, for a randomized mechanistic clinical trial testing a collaborative care intervention for postpartum hypertension in Black women under the Cardiovascular Diseases Research program (CFDA 93.837). The study, titled PRIME CARE (Postpartum Remote Monitoring and Integration of Mobile...
- The National Heart, Lung, and Blood Institute awarded the Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center $161,500 on August 20, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to support planning activities for a future multisite cluster randomized trial on hypertensive disorders of pregnancy prevention in safety-net clinics. The award funds a preparation phase to evaluate the feasibility and acceptability of implementation intervention...
- The National Heart, Lung, and Blood Institute awarded the University of Alabama at Birmingham $734,986 on August 4, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to conduct genetic architecture research on natriuretic peptides and their role in blood pressure regulation. The research leverages whole genome sequencing data from multiethnic cohorts—including the Transomics for Precision Medicine cohorts, UK Biobank, and All of Us Research Program—to identify common,...
- The National Heart, Lung, and Blood Institute awarded Vanderbilt University Medical Center $154,142 on July 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to study preeclampsia recurrence risk and identify mitigation strategies. The award funds a five-year research and career development project running through June 30, 2031, centered at Nashville, Tennessee. The research establishes the relationship between preeclampsia subtypes and recurrence risk in a...
- The National Heart, Lung, and Blood Institute awarded the University of Alabama at Birmingham $1,254,849 on September 16, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop engineered small extracellular vesicles for treating diabetic ischemic heart failure. The research addresses the mechanism by which type 2 diabetes confers treatment resistance in ischemic heart failure, focusing on downregulation of CTRP9, a cardioprotective cardiokine that impairs small...
- Federal Project Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded the University of Alabama at Birmingham $223,438 on September 4, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837) to conduct a clinical research study examining hypertension incidence in people with HIV initiating antiretroviral therapy (ART). The project, scheduled for completion by August 31, 2027, will assess blood pressure outcomes in ART-naïve individuals starting either...
- The National Heart, Lung, and Blood Institute awarded The General Hospital Corporation (Massachusetts General Hospital) $3,330,084 under the Cardiovascular Diseases Research program (CFDA 93.837) on August 10, 2026, for a project grant investigating causal links between the maternal plasma proteome, preeclampsia, and future cardiovascular disease. The research leverages proteomic analysis of circulating microparticles isolated from maternal plasma samples collected across first, second, and...
- The National Institutes of Health National Heart Lung and Blood Institute awarded the University of Pittsburgh $190,168 on July 2, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to support Dr. Malamo Countouris's research into reversing left ventricular remodeling in women with a history of preeclampsia and current hypertension. The award funds Dr. Countouris's career development as an independent physician-scientist and clinical trial leader in cardio-obstetrics. The...
- The National Heart, Lung, and Blood Institute awarded Women & Infants Hospital of Rhode Island $244,569 on July 15, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to conduct a single-site randomized controlled trial piloting the feasibility and efficacy of postpartum enalapril treatment for cardiovascular protection in women with a history of preeclampsia. The trial will enroll women within the hospital's remote blood pressure management program to assess whether...
- The National Heart, Lung, and Blood Institute awarded the University of Alabama at Birmingham $754,413 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to conduct a randomized controlled trial of remote blood pressure monitoring, pharmacist-led telehealth medication management, and automated text reminders integrated into an emergency department transitional care clinic model for hypertensive patients. The trial, titled REMAP-BP (Remote Blood Pressure...